Amended Press Release: Maricann Group Inc. Signs Letter of Intent with Lovell Drugs
This is a collaborative retail initiative between Lovell Drugs Ltd. and Maricann Group Inc.
Company is deepening its relationships with the pharmacy sector
TORONTO, ONTARIO–(Marketwired – Nov. 13, 2017) –
Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF) (“Maricann” or the “Company”) is pleased to announce that it has entered into a letter of intent with Lovell Drugs Limited (“Lovell Drugs”), one of the oldest independent drug store chains in Ontario, to be the primary and exclusive provider of medicinal cannabis products to its patients through a two part initiative, consisting of;
- Education: Maricann and Lovell Drugs will jointly develop a patient and healthcare education program for Lovell Drugs retail pharmacies to assist them in acquiring the requisite expertise to provide counseling about all aspects of medicinal cannabis. Maricann and Lovell Drugs will also work together to develop procedures and protocols for providing patients of Lovell Drugs with access to such educational content.
- Product Accessibility: Lovell Drugs and Maricann will work together to develop medical cannabis product accessibility initiatives designed to facilitate the sale and distribution of Maricann’s products to patients seeking cannabis through Lovell Drugs retail pharmacies, to the extent permitted by applicable law, as well as education and content relating to the handling and dispensing of medicinal cannabis. In connection with this effort Lovell Drugs will designate Maricann as its exclusive medical cannabis provider.
We believe that pharmacies are the best distribution points for medicinal cannabis, as is the case for all other prescriptions. That’s why we are so pleased to be working with Lovell Drugs in finding ways to provide Maricann’s differentiated medical cannabis education and products for their patients. Lovell’s pharmacists are trusted health care professionals, providing services such as Clinic Days, MedsChecks, blood pressure tests, smoking cessation products, and cholesterol testing for their patients.
Ben Ward, CEO of Maricann
The contemplated term of the agreement is four years, with an option to extend another three years if the parties mutually agree. The letter of intent will form the basis of a definitive agreement to be executed by the parties at a future date. A further announcement will be made upon the execution of the definitive agreement.
Signing this letter of intent with Lovell Drugs builds on Maricann’s deepening relationships with pharmacists across Canada. On November 6, 2017, Maricann announced that it had entered into a definitive agreement to create a similar pharmacy services program with a national provider that services over 2,000 pharmacies across Canada.
About Maricann Group Inc.
Maricann, which has federal licenses in Canada to cultivate, extract, formulate and distribute cannabis, is rapidly expanding its Canadian production, based in Norfolk County, Ontario, targeting to add 22,245 kg of annual production of dry flower to come online in Q2 2018, with additional production planned. The Company announced on November 8, 2017 that Health Canada had granted Maricann Group Inc. a new licence that removes annual production limits on approved medical cannabis products in its Canadian growing facility.
For more information about Maricann, please visit our website at www.maricann.ca
